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Abstract 
 Diabetes is not commonly thought to be a women’s health issue, however, it appears to 
have an association with increased cognitive impairment in women during menopause as 
compared to women without diabetes (Espeland et al., 2011). The present study investigated the 
effects of type II diabetes and menopause on cognition in women between the ages of 46 and 55 
years. To assess cognition, participants performed the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS; Randolph 1998), Letter Number Sequencing Test 
(Wechsler, 1997), Trail Making Test (Delis, 2001), Verbal Fluency Test (Delis, 2001), Wechsler 
Test of Adult Reading (Wechsler, 2001), and the Buschke Selective Reminding and Delayed 
Recall Tests (Buschke, 1974). Participants also answered questionnaires on mood, diabetes, and 
hormone and reproductive history. No premenopausal women or perimenopausal women with 
diabetes participated. Women were divided into the following groups to examine the interactions 
of diabetes and hormones on cognition: perimenopausal women without diabetes, 
postmenopausal women with diabetes, and postmenopausal women without diabetes. It was 
predicted that women with diabetes would score lower on all tests, with an emphasis on 
difficulties with executive function and memory. Postmenopausal women with diabetes showed 
lower scores in working memory, executive control, visual attention, task switching, and 
episodic memory as seen in data from the Letter Number Sequencing Test, Verbal Fluency Test, 
Trail Making Test, and Buschke Selective Reminding and Delayed Recall Tests, respectively. 
Perimenopausal women without diabetes showed lower scores than postmenopausal women with 
and without diabetes on verbal memory and executive control. The sample of eight women was 
small, though there were indications of differences between groups highlighting the need for 
further research.  
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I. Introduction and Previous Work 
Recent research has shown that metabolic diseases and cardiovascular risk factors, such 
as obesity, insulin resistance, and type II diabetes, may lead to an increased risk for cognitive 
decline and even Alzheimer’s disease or vascular dementia (Neth, 2017). While diabetes may not 
commonly be viewed as a women’s health issue, there are data to suggest that it may negatively 
impact women during reproductive aging. Women are at higher risk than men for cardiovascular 
disease, hypertension, stroke, and coronary artery disease, all of which are associated with 
diabetes as reviewed by Coker (2003). Due to the cognitive impairment associated with diabetes 
and menopause independently, women may also be at higher risk for peripheral vascular disease, 
dementia, and Alzheimer’s disease (Mcneill et al., 2018). Thus far, research has focused on 
cognitive impairment in older women with diabetes and there are very few studies examining 
how diabetes interacts with menopause to affect cognition.  This study attempted to take a closer 
examination of the relationships between cognition, menopause, and diabetes in middle-aged 
women to see how diabetes affects the brain in women at different stages of the menopause 
transition. This could allow for researchers to determine which stage of menopause is associated 
with the most adverse effects and potentially mitigate cognitive decline in the future.  
Menopause and Cognition 
 Menopause affects all women and has many effects on the brain. Understanding the 
menopause transition is important for examining the health effects in middle-aged women. A 
woman is considered postmenopausal after 12 months of amenorrhea due to permanent cessation 
of ovarian function (Greendale et al., 1999). The menopause transition typically occurs around 
51 years. Three important phases include premenopause, perimenopause, and postmenopause. 
Premenopause refers to women still experiencing regular menstrual cycles (Davis et al., 2015). 
Bates, Kara: DIABETES, MENOPAUSE, AND COGNITION 
 
 7 
Menstrual cycles are considered regular if they last 25 to 35 days (Casper, 2017). Perimenopause 
refers to women experiencing irregular menstrual cycles due to changes in ovarian function 
(Greendale et al., 1999). Menstrual cycles are considered irregular if they last more than 60 days 
(Davis et al., 2015). Additionally, a woman is perimenopausal if she has had at least one period 
in the last 12 months (Cheung et al., 2004). Lastly, postmenopause refers to women who have 
not experienced menstrual cycles for 12 months (Dalal et al., 2015). Various symptoms may be 
experienced throughout the menopausal transition including hot flashes, urinary incontinence 
(sensations of frequency and urgency), vaginal atrophy (signs may include vaginal dryness, 
itching, and irritation), reduced sexual dysfunction, and depression (Greendale et al., 1999).  
The menopause transition can have negative effects on the brain, especially in terms of 
memory and thinking related to the changing hormone levels. Common symptoms associated 
with menopause involve confusion, forgetfulness, and fuzzy thinking (Mitchell et al., 2001). 
Schaafsma et al. (2010) found subjective cognitive complaints to be associated with measurable 
declines in verbal memory and attention, which was specifically notable in the perimenopausal 
group as compared to premenopausal and postmenopausal groups. Additionally, a review by 
Weber et al. (2014), found for a measure of executive function, postmenopausal women 
performed significantly worse than perimenopausal women on verbal fluency tasks. On measures 
of verbal memory, postmenopausal women also performed significantly worse than 
perimenopausal women on immediate memory as well as immediate and delayed verbal recall. 
This shows that the menopause transition has negative effects on cognition. Greendale et al. 
(2009) found a different pattern of results in a longitudinal study of cognitive performance across 
the menopause transition. This large-scale (n=2,362), longitudinal study consisted of four follow 
up visits over the course of four years. Slopes of cognitive scores were calculated using the data 
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collected from women to predict their scores across hormone changes. The perimenopausal 
women experienced the most memory difficulties while improvement to premenopausal levels 
was noted in their postmenopausal states. These data suggest that cognitive impairment may only 
occur for a period of time during the fluctuating hormone phase before a woman is 
postmenopausal (Greendale et al., 2009). Similarly, in a cross-sectional study (n=103), Weber et 
al. (2013) found that women in their first year of postmenopause performed significantly worse 
than premenopausal and late-postmenopausal women on tasks including verbal learning, verbal 
memory, and attention/working memory. These data also suggest that the brain may have the 
ability to adjust and compensate for hormone changes later in life.   
When women go through menopause, whether they do so naturally or via surgery, there 
are decreased levels of 17𝛽-estradiol (E2; Au et al., 2016). E2 decline during menopause is 
associated with cognitive functioning decline and an increase in depressive problems (Weber at 
al., 2014). A previous menstrual cycle study showed that when estrogen levels are high, women 
excel on tests including verbal articulation, fluency, and perceptual speed (Mitchell et al., 2001). 
Additionally, the use of estrogen hormone therapy, which is used to control menopause 
symptoms, can reduce aging effects on cognition and assist prefrontal mechanisms if taken 
during early-postmenopause (Girard et al., 2017). However, when given to older women it may 
result in slight decreases in cognitive functioning that lasts for a few years post-medication 
termination (Espeland et al., 2017). Estrogen’s apparent protective effect on cognitive 
functioning is lost at menopause (Morgan et al., 2018). Estrogen can stimulate neurotransmitters 
and blood flow to the brain as well as promote neuronal and synaptic growth within the 
hippocampus and cortex, all of which are important for learning, memory, and cognition 
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(Morgan et al., 2018). How estrogen protects the brain is still not fully understood. However, 
data show that middle-aged women are at risk for cognitive impairment due to hormone changes. 
Diabetes and Cognition 
 Type II diabetes is becoming increasingly more prevalent in the Unites States as obesity 
rates and sedimentary lifestyles rise. Overall prevalence of diagnosed diabetes based on the 
NIHS 2011-2015 was 21.8 million individuals in the United States (Cowie et al., 2018). The 
current diabetes epidemic shows increased necessity for research in how this disease affects all 
aspects of health. Understanding the toll that diabetes has on the brain is important because these 
effects may be worsened in women during the menopause transition. 
 Individuals with type II diabetes are incapable of normal regulation of glucose 
metabolism, meaning they are insulin resistant (Kahn et al., 2013). Insulin resistance, the body’s 
inability to use insulin properly, is when there is an impaired response to insulin leading to the 
body’s inability to remove glucose from the bloodstream. This leads to hyperglycemia, which is 
an abnormal rise in blood glucose levels. A feedback loop between 𝛽-cells and insulin sensitive 
tissues is crucial to glucose homoeostasis in the body (Kahn et al., 2013). If 𝛽-cells cannot 
properly control insulin output to regulate glucose levels, there will be an increase in glucose 
(Kahn et al., 2013).  
Research suggests that chronic type II diabetes can negatively impact the brain via 
accelerated cognitive dysfunction and increased risk for dementia (Klein et al., 2003). This exact 
mechanism is not fully understood. It is hypothesized that impaired metabolic processes in 
individuals with diabetes lead to insulin resistance, poor glycemic control, and inflammation, 
which may cause the secondary end-organ damage seen in the brain (Yoon et al., 2017). Klein et 
al. (2003) proposed another mechanism of pathogenesis in which there may be changes in the 
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gene expression of neurons. These changes in neuronal structure and function may lead to 
disruptions in cognitive processes in the brain, resulting in the notable cognitive impairment seen 
in individuals with diabetes.   
Prior research studies examined cognition via cognitive batteries in men and women aged 
40 to 80 years and found significant impairments in memory and executive function in the 
participants with diabetes. In a study conducted by Knopman et al. (2001) cognitive assessments 
including Delayed Word Recall, the Digit Symbol Subtest of the Wechsler Adult Intelligence 
Scale, and a First-Letter Word Fluency Test were administered to individuals between the ages 
of 47 and 70 years with and without diabetes. Both subjects with diabetes younger than 58 years 
and older than 58 years performed significantly worse on the Digit Symbol Subtest as well as the 
First-Letter Word Fluency Test as compared to subjects without diabetes (Knopman, 2001). The 
Digit Symbol Subtest measures processing speed, working memory, and attention while the 
Verbal Fluency Test measures executive control, which are all components of executive 
function. Diabetes was a risk factor for cognitive decline in even the younger age group.  
Imaging studies found similar results in that adults with diabetes showed increased 
temporal horn volume thus leading to deficits in memory and executive function (Debette, 2011). 
This study also examined vascular risk factors in relation to how they may accelerate structural 
brain aging and cognitive decline. MRIs of middle-aged individuals, a mean age of 54 years, 
with diabetes showed a far more rapid increase in temporal horn volume, an indicator of 
hippocampal atrophy. These degenerative changes in brain structure were correlated with 
cognitive decline including deficits in memory and executive function. This study examined 
longitudinal change of various quantitative MRI markers of cognitive decline as well as 
longitudinal change in cognitive test scores (Debette, 2011). Another study conducted by Heijer 
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et al. (2003) also examined this relationship using MRIs to examine atrophy of medial temporal 
lobe structures. The one important difference in this study compared to others is that they 
questioned whether diabetes simply increased the risk of Alzheimer’s disease due to its vascular 
components or if diabetes directly caused Alzheimer neuropathology to develop (Heijer et al. 
2003). Their results yielded more hippocampal and amygdalar atrophy on MRI in the subjects 
with diabetes. However, in individuals without diabetes, insulin resistance was associated with 
only amygdalar atrophy on MRI. Hippocampal and amygdalar atrophy was used in this study as 
a marker of preclinical Alzheimer’s disease, as this was also associated with memory impairment 
and development of other symptoms of dementia later in life (Heijer et al. 2003). These findings 
indicate that diabetes influenced neurodegeneration and that this influence changed across the 
age span (Knopman, 2001).  
There have been inconsistencies across results of similarly designed studies. Scott et al. 
(1998) did not find an association between diabetes and cognitive function in older subjects. This 
study utilized 12 cognitive tests and no significant results were found. The researchers suggested 
that subjects in studies where cognitive decline was found may have been experiencing 
temporary deficits due to ischemia or injury to the brain, which occurs in patients with diabetes. 
Additionally, subjects in these prior studies may have suffered from repeated, severe 
hypoglycemic episodes, explaining the impairment in cognition (Scott, 1998). The researchers 
did note, however, that women with diabetes performed worse on all cognitive tests but not at a 
significant level. It is clear that the association between diabetes and cognition is not fully 
understood and further studies are needed.  
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Diabetes, Menopause, and Cognition 
No study described above explicitly examined the role of sex on cognitive changes in 
diabetes, though data suggested that females with diabetes experienced more cognitive 
impairment than males with diabetes (Knopman, 2001). Women with type II diabetes tend to be 
significantly younger at menopause as compared to women without diabetes (Mauvais, 2017). 
Menopause is associated with increased visceral fat, a decrease in lean body mass, and changes 
in body composition that can lead to impaired insulin sensitivity, which are risk factors for type 
II diabetes in postmenopausal women (Mauvais, 2017). As mentioned earlier, estrogen seems to 
have a protective effect on cognition. Therefore, this increased risk for cognitive decline caused 
by the reduction of protective effects of estrogen paired with increased vascular disease 
associated with diabetes, such as hypertension, obesity, and high cholesterol, may affect 
cognitive functioning.  
There seems to be an interaction between estrogen via hormone therapy and insulin and 
the delayed onset of diabetes (Mauvais, 2017). Menopausal hormone therapy may improve islet 
-cell function, insulin secretion, noninsulin-dependent glucose disposal, and glucose 
effectiveness in postmenopausal women, though it is not approved by the FDA specifically for 
the use of diabetes prevention due to complex possible risks and benefits (Mauvais, 2017). 
Research by Espeland et al. (2015) found that older postmenopausal women with diabetes 
showed brain atrophy via decreased gray matter volumes when taking hormone therapy in a 
randomized clinical trial. Espeland et al. (2015) also noted that high levels of estrogen via 
postmenopausal hormone therapy may increase the risk of cognitive impairment in diabetes. The 
effects of estrogen hormone therapy on diabetes is still unclear though studies are currently being 
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conducted to examine the potential for protective mechanisms of postmenopausal hormone 
treatment in women with diabetes (Mauvais, 2017).  
Prior studies have examined the effect of diabetes on cognitive impairment in older 
women. Studies conducted by Logroscino et al. (2004) and Gregg et al. (2000) administered 
multiple cognitive tests to women with and without diabetes. Logroscino et al. (2004) included 
women between 70 and 81 years who completed a baseline interview of their cognitive state and 
the women with diabetes performed significantly worse on all cognitive tests. The cognitive tests 
were Immediate and Delayed Recall, Verbal Fluency Tests, and a Digit Span Backwards Test. A 
global score was made from the results of these tests. These results suggested impairments in 
working memory and attention which are components of executive functioning. It was also noted 
that women who had a longer duration of diabetes had evidence of further impaired cognition. 
Women utilizing oral hypoglycemic agents, which are medications that decrease blood glucose 
levels like metformin, performed in a similar manner to women without diabetes, however, 
women not taking these medications displayed the poorest performance of all groups. Those 
experiencing improved glucose control via oral medications were found to have better cognitive 
performance, memory, and orientation, suggesting that oral therapy may benefit the cognitive 
health of individuals with diabetes. Logroscino et al. (2004) did not offer reason as to why this 
was the case, though it may be that the oral medications were able to control glucose levels and 
prevent the secondary end-organ damage seen in the brain. Gregg et al. (2000) had similar 
findings in that women with diabetes who were 65 years and older performed significantly worse 
on the Digit Symbol Test, Trail B Test, and Mini Mental State Examination. This indicated that 
women with diabetes showed declines in concentration, language, and memory as measured by 
the Mini Mental State Examination. Additionally, their scores on the Digit Symbol Test 
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suggested declines in attention, psychomotor performance, and perceptual organization. Lastly, 
their scores on the Trail B Test suggested declines in attention and visual scanning. Women who 
were not taking insulin had a significantly higher risk of cognitive decline than those who were. 
These data are similar to that of Logroscino et al. (2004) in that medication aiding glucose 
tolerance, in the form of insulin, seemed to assist in the prevention of the negative effects of 
diabetes on the brain. In other words, medications that help regulate glucose metabolism, thus 
preventing hyperglycemic events in individuals with diabetes, may prevent some of the cognitive 
impairment individuals not taking these medications may experience. Memory problems were 
reported with a higher frequency in the group with diabetes as compared to the group without 
diabetes. Similar to the previous study, the cognitive decline increased with duration of diabetes. 
Gregg et al. (2000) did not assess the presence of other components of diabetes including oral 
medications, glycemic control, and neuropathies. Due to this limitation, our study included an 
assessment of such components for the subjects with diabetes. Neither of these studies examined 
brain structure via imaging nor did they attempt to examine the mechanism by which diabetes 
affected cognition.   
The Current Study 
In the Dumas Lab, menopause and cognition have been studied extensively. The aim of 
this thesis was to examine the effect of diabetes on cognition in women at different stages of the 
menopause transition. This study attempted to investigate the relationship between menopause 
and diabetes and their combined effect on cognition. While Gregg et al. (2000) found significant 
cognitive decline in older postmenopausal women with type II diabetes, no studies have 
examined middle-aged women with diabetes. This age group is important to study because 
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cognitive decline may start in middle adulthood in subjects with diabetes and the role of sex and 
menopause on diabetes and cognition has not yet been examined.  
 I hypothesized that women with diabetes would score lower on all cognitive tests due to 
decreased executive functioning and that this decreased cognitive functioning would be greater 
in women who are further along the menopause transition. I hypothesized that executive 
functioning, specifically, would show notable decline and this hypothesis is supported by the 
prior research (Knopman et al. 2001; Logroscino et al. 2004; Gregg et al. 2000). Within the 
group of women with diabetes, I hypothesized that premenopausal women would show the least 
cognitive deficits while postmenopausal women would show the most cognitive deficits. Within 
the group of women without diabetes, I hypothesized, again, that premenopausal women would 
show the least cognitive deficits while postmenopausal women would show the most cognitive 
deficits.  
 
II.  Methodology 
Participants 
Recruitment flyers were placed in the city of Burlington and surrounding towns. Diabetes 
clinics and doctors’ offices across the state of Vermont were contacted and given flyers. An ad 
for subjects with diabetes ran in Seven Days for two weeks. Participants were required to 
complete a brief phone screening interview to determine their eligibility for the study. Once 
determined eligible, an appointment was scheduled for a two-hour study visit at the University 
Health Center where subjects were consented and asked to complete various cognitive tests and 
questionnaires regarding their medical history. Inclusion criteria included women between the 
ages of 45 and 55 years who were either healthy or had type II diabetes. There were no other 
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exclusion criteria for the pilot study apart from women who could not complete the cognitive 
tasks and questionnaires. Eight women were recruited for the study. 
Measures 
General Cognitive Health Assessments: Subjects completed interview-based 
assessments or questionnaires to assess the presence of dementia, depressed feelings, sleep 
quality, and IQ. These cognitive and behavior assessments are standardized tests designed to 
identify women with significant cognitive or behavioral impairment. The Mini Mental State 
Exam is a dementia assessment instrument (Folstein et al., 1975). To evaluate current depression, 
subjects completed the Beck Depression Rating Scale (Beck et al. 1961). The Pittsburgh Sleep 
Quality Index was used to assess sleep quality over a one-month interval (PSQI; Buysse et al. 
1989). Lastly, subjects performed the Wechsler Test of Adult Reading (WTAR) to estimate IQ 
(Wechsler, 2001). 
Diabetes. In order to determine if subjects had type II diabetes, their medical records 
were examined and they were classified as having diabetes if they had been officially diagnosed 
by a physician. Subjects with diabetes were required to complete a Diabetes History Form 
(Columbia Medical Associates, 2016) to obtain more information regarding disease duration, 
physical activity, complications, and diabetes care. 
Reproductive Hormone History. Women were asked various questions about their 
menstrual cycle history to classify them as pre-, peri-, and postmenopausal. Women were 
considered premenopausal if they still had regular menstrual cycles and were not yet menopausal 
(Davis et al., 2015). Regular menstrual cycles refer to menstrual cycles lasting 25 to 35 days 
(Casper, 2017).  Women were considered perimenopausal if they had been experiencing irregular 
menstrual cycles and at least one period in the past 12 months (Cheung et al., 2004). Irregular 
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menstrual cycles refer to a menstrual cycle lasting more than 60 days (Davis et al., 2015). 
Women were considered postmenopausal if it had been 12 months since their last menstrual 
cycle (Dalal et al., 2015). All women completed the Indices of Estrogen Exposure Questionnaire 
(Lord et al. 2009). This questionnaire is a measure of life time estrogen exposure and inquired 
about menstrual cycles, motherhood, menopause, and history of hormone therapy. Additionally, 
all women completed a Menopause Symptom Checklist (Newhouse and Sargent 2002). 
Neuropsychological Testing. The cognitive measures for this study included the 
following: Repeatable Battery for the Assessment of Neuropsychological Status, Letter Number 
Sequencing Test, Buschke Selective Reminding and Delayed Recall Tests, Trail Making Test, 
and Verbal Fluency Test. To assess general neuropsychological functioning, all women 
performed the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; 
Randolph 1998). The RBANS assessed five cognitive domains including immediate memory, 
language, visuospatial/constructional ability, attention, and delayed memory and provides a 
global total measure. The Letter Number Sequencing Test was used as a measure of working 
memory ability, in which subjects were asked to reorder sequences of numbers first numerically 
and letters second alphabetically to the researcher. The Buschke Selective Reminding and 
Delayed Recall task involved the subject listening to 16 words and then recalling as many words 
as they could. The researcher then reminded the subject of the words she was unable to recall and 
the task was to try to recall the whole list again (Buschke, 1974). The Trail Making Test and 
Verbal Fluency subtests from the Delis-Kaplan Executive Function System (D-KEFS) were 
included. The Trail Making Test required subjects to connect circles that are distributed over a 
sheet of paper as quickly as possible. There were four parts to this test, each involving different 
conditions to assess visual attention and task switching. The Verbal Fluency subtests required 
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subjects to produce as many words as possible from a given category in one minute to examine 
executive control and verbal ability. 
Statistical Analysis 
 Due to the difficulty in recruitment of this age group of women, means and standard 
deviations are presented to begin to examine cognitive performance in women with and without 
diabetes at different stages of the menopausal transition. We did not compute statistics on this 
sample as parametric analyses that assume normal distributions of the data will be unreliable 
with such a small sample size. In addition, while non-parametric analyses can be conducted on 
data with non-normal distributions, the groups in this study are still too small to produce reliable 
results.  
 
III.  Results 
Demographics 
 The total number of participants acquired for this study was eight, consisting of two 
women with diabetes and six women without diabetes. The two women with diabetes were 
postmenopausal with a mean age of 52.5 (SD=3.5). Of the six women without diabetes, three 
were perimenopausal with a mean age of 49.3 (SD=3.9) and three were postmenopausal with a 
mean age of 51.0 (SD=4.8). No premenopausal women participated in the study. All of these 
subjects were high functioning women with at least a high school degree or more.  
Table 1: Demographic data of all subjects included in the study including their age (M=50.6, SD=3.5), 
stage of menopause, diabetes diagnosis, and education level.  
 
 Diabetes 
Postmenopausal 
No Diabetes 
Perimenopausal 
 
Postmenopausal 
Number of Subjects 2 3 3 
Age in years (M, SD) 52.5 (3.5) 49.3 (2.9) 51.0 (4.8) 
Education, Years (M, SD) 16.0 (2.0) 16.7 (1.2) 14.0 (2.8) 
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Menopause: Of the postmenopausal women, one had surgical menopause via a 
hysterectomy while the rest had natural menopause. The mean menopause duration in 
postmenopausal women with diabetes was 6 years (SD= 1.4). The mean menopause duration in 
postmenopausal women without diabetes was 7.5 years (SD= 7.5). One postmenopausal woman 
without diabetes was on a low dose topical progesterone hormone therapy for 12 months about 
two years prior to her study visit. No other women reported use of hormone therapy.  
Women varied greatly in number and severity of menopause symptoms experienced. The 
pattern of the means showed that postmenopausal women with diabetes reported high frequency 
and severity of menopause symptoms (M=59.5, SD=3.5). Postmenopausal women without 
diabetes reported a higher frequency and severity of menopause symptoms (M= 44.3, SD=36.7) 
than perimenopausal women without diabetes (M=32.7, SD=39.3). Symptoms experienced by 
more than half of the subjects included irritability, mood swings, worrying needlessly, 
constipation, leg cramps, intestinal gas, fatigue, early awakening, and muscle stiffness.  
Diabetes: The duration of diabetes varied amongst the two subjects with diabetes. One 
woman was diagnosed 13 years ago and the other was diagnosed three years ago. Both subjects 
were taking metformin and insulin to control their sugar levels. Both subjects reported not 
exercising regularly. One subject experienced a hypoglycemic event that was treated with 
glucose tablets. Neither subject had been hospitalized for their diabetes.  
Global Cognitive Health  
 Overall, all subjects displayed scores on the MMSE, WTAR, Beck Depression Rating 
Scale, and PSQI that did not indicate severe cognitive problems. The postmenopausal group with 
diabetes showed the highest scores on the Beck Depression Rating Scale and PSQI indicating 
higher rates of depressive symptoms and decreased sleep quality. 
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Table 2: Means and standard deviations from MMSE, WTAR, Beck Depression Rating Scale, and PSQI 
that assessed general cognitive health of the subjects. Overall, all eight subjects did not show severe 
cognitive problems. 
 
 
 
Test 
 
Diabetes 
Post 
 
No Diabetes 
Peri 
 
 
Post 
MMSE 29.5 (0.7) 29.3 (0.6) 30.0 (0.0) 
WTAR 110.5 (17.7) 118.0 (7.6) 123.3 (1.5) 
Beck 9.0 (5.7) 3.7 (5.5) 7.0 (4.6) 
PSQI 7.5 (2.1) 5.3 (2.5) 3.7 (1.5) 
 
Neuropsychological Data 
RBANS: Postmenopausal women with diabetes showed higher scores than both 
perimenopausal and postmenopausal women without diabetes on the total scale. Postmenopausal 
women with diabetes also showed higher scores than both groups on immediate memory, 
visuospatial/constructional, language, and delayed memory. However, postmenopausal women 
with diabetes showed lower scores than perimenopausal and postmenopausal women without 
diabetes in the attention conditions, which included a digit span and a coding task, where 
subjects had to match symbols to their corresponding numbers as quickly as possible. 
Additionally, perimenopausal women without diabetes showed lower scores than 
postmenopausal women without diabetes on most conditions except attention and 
visuospatial/constructional conditions, which included figure copying and line orientation. 
Table 3: Means and standard deviations from RBANS. Women with diabetes performed better than 
women without diabetes. The perimenopausal group showed slightly lower scores on all tasks except 
attention and visuospatial/constructional. 
 
 
 
Test 
Diabetes 
 
Post 
No Diabetes 
 
Peri 
 
 
Post 
Immediate Memory 116.0 (14.1) 106.3 (18.2) 109.7 (4.0) 
Visuospatial/Constructional 112.5 (4.9) 111.7 (8.3) 111.3 (17.5) 
Language 114.0 (24.0) 106.0 (6.1) 110.7 (9.1) 
Attention 108.0 (24.0) 117.7 (10.2) 108.7 (26.5) 
Delayed Memory 114.5 (13.4) 106.7 (1.5) 110.0 (5.0) 
Total Scale 119.5 (19.1) 113.7 (8.0) 114.3 (15.3) 
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Letter Number Sequencing: Perimenopausal women (M=13.0, SD=7.1) and 
postmenopausal women with diabetes (M=13.3, SD=2.9) showed similar scores on the Letter 
Number Sequencing Test. Postmenopausal women without diabetes (M=11.0, SD=1.7) showed 
lower scores than both groups suggesting differences in working memory. 
Trail Making: Postmenopausal women with diabetes had lower contrast scores than 
perimenopausal and postmenopausal women without diabetes. Low contrast scores indicate 
possible cognitive problems specifically in visual scanning and attention. Additionally, 
perimenopausal women without diabetes scored slightly lower on contrast scores as compared to 
postmenopausal women without diabetes. 
Table 4: Means and standard deviations from the Trail Making Test. The composite score is the sum of 
the scaled number sequencing and letter sequencing scores. VS Contrast is the difference between the 
scaled switching score and scaled visual scanning score. NS Contrast is the difference between the scaled 
switching score and the scaled number sequencing score. LS Contrast is the difference between the scaled 
switching score and the letter sequencing score. Com Contrast is the difference between the scaled 
switching score and the composite score. Postmenopausal women with diabetes scored lower than peri- 
and postmenopausal women without diabetes on most measures.  
 
 
 
Test 
Diabetes 
 
Post 
No Diabetes 
 
Peri 
 
 
Post 
Composite 12.5 (3.5) 12.3 (0.6) 12.7 (2.5) 
VS Contrast 6.0 (7.1) 11.3 (1.5) 12.3 (1.2) 
NS Contrast 5.5 (3.5) 11.0 (1.0) 11.7 (0.6) 
LS Contrast 6.0 (7.1) 11.3 (1.2) 11.3 (2.5) 
Com Contrast 5.5 (6.4) 10.0 (0.0) 13.0 (5.2) 
 
Buschke Selective Reminding and Delayed Recall: Postmenopausal women without 
diabetes recalled more words in both the immediate and delayed recall conditions as compared to 
perimenopausal women without diabetes. Postmenopausal women with diabetes showed better 
scores than perimenopausal women without diabetes in all conditions. Postmenopausal women 
without diabetes showed better scores than postmenopausal women with diabetes in all 
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conditions. These patterns show differences in episodic memory in postmenopausal women with 
diabetes compared to postmenopausal women without diabetes.  
Table 5: Means and standard deviations from Buschke. Postmenopausal women without diabetes showed 
better scores on all tasks as compared to perimenopausal women and postmenopausal women with 
diabetes. 
 
 
 
 
Test 
 
Diabetes 
 
Post 
 
No Diabetes 
 
Peri 
 
 
 
Post 
Total Recall 89.5 (17.7) 77.3 (0.6) 95.0 (9.9) 
Total Consistency 60.5 (23.3) 44.0 (5.3) 66.0 (16.1) 
Total Recall Failure 11.5 (12.0) 16.7 (3.2) 6.3 (4.5) 
Total Delayed Recall 12.5 (3.5) 8.0 (1.0) 12.3 (3.1) 
 
Verbal Fluency: Perimenopausal women without diabetes showed lower scores than 
postmenopausal women without diabetes on all conditions. Perimenopausal women without 
diabetes also showed lower scores than postmenopausal women with diabetes on all conditions 
except condition 1, letter fluency. Additionally, postmenopausal women with diabetes showed 
lower scores than postmenopausal women without diabetes on all conditions except condition 3a, 
total correct responses in category switching.  
Table 6: Means and standard deviations from Verbal Fluency Test. Condition 1 is letter fluency, 
condition 2 is category fluency, condition 3a is total correct responses in category switching, and 
condition 3b is total switching accuracy in category switching. Perimenopausal women showed lower 
scores than postmenopausal women with and without diabetes on all tasks except letter fluency. 
Postmenopausal women with diabetes showed lower scores than postmenopausal without diabetes on all 
tasks except total correct responses in category switching. 
 
 
 
 
Test 
 
Diabetes 
 
Post 
 
No Diabetes 
 
Peri 
 
 
 
Post 
Condition 1 9.5 (3.5) 12.0 (4.4) 14.7 (3.1) 
Condition 2 13.0 (1.4) 13.0 (1.0) 15.0 (3.6) 
Condition 3a 13.0 (2.8) 7.7 (7.6) 12.7 (4.7) 
Condition 3b 12.0 (1.4) 7.0 (7.2) 12.3 (4.2) 
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IV. Discussion 
The aims of this study were to examine how cognition differs between women with 
diabetes and women without diabetes who are at different stages of the menopause transition. It 
was predicted that women farther along in reproductive aging would experience the most 
cognitive impairment, in that postmenopausal women would perform worse than perimenopausal 
women. It was also hypothesized that type II diabetes would cause increased cognitive 
impairment as compared to women without diabetes. Due to the small sample size, we chose not 
to compute statistics on the data, thus we could not tell if the differences between the groups 
were due to chance or not. However, the data show some interesting trends that are both similar 
to and different from the previous research, highlighting the need for further investigation.  
Postmenopausal women with diabetes showed higher scores than women without 
diabetes on components of the RBANS, including immediate memory, language, delayed 
memory, and the total scale. Women with diabetes also showed better scores than 
perimenopausal women without diabetes on the episodic memory via the Buschke Selective 
Reminding and Delayed Recall Tests. These results differ from my hypothesis. This may be due 
to the small sample size, or it may be possible that diabetes may be associated with better 
cognition on these cognitive domains. This suggestion, however, is not supported by previous 
research. 
Perimenopausal women without diabetes showed lower scores than postmenopausal 
women without diabetes on parts of the RBANS and Verbal Fluency Tests that show differences 
in working memory, executive function, language, and visuospatial/constructional ability. This is 
different from previous research by Weber et al. (2014) in that postmenopausal women showed 
measurable declines in verbal memory and immediate and delayed recall as compared to 
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perimenopausal women. These results could be a random pattern due to the small sample. 
Perimenopausal women also showed better scores than both groups of postmenopausal women 
on the attention component of the RBANS Test, as predicted. Perimenopausal women also 
showed similar scores as postmenopausal women without diabetes on the Trail Making Test, 
which measures attention and visual acuity. Both perimenopausal and postmenopausal women 
without diabetes also showed similar scores on the Letter Number Sequencing Test.  
It is possible that the postmenopausal women without diabetes in this study, who had a 
mean duration of menopause of 7.5 years, may have been postmenopausal long enough for their 
bodies to begin to compensate for the loss of estrogen. Weber et al. (2013) and Greendale et al. 
(2009) noted that women who are late-postmenopausal may begin to experience improved verbal 
learning, verbal memory, and attention/working memory back to their baseline, premenopausal 
state. Early-postmenopause was defined as less than 12 months postmenopausal by Weber et al. 
(2013). Using this definition, all postmenopausal women in our study could be classified as late-
postmenopausal as they have been postmenopausal for 6.75 years on average. This may support 
our findings in that perimenopausal women showed lower scores than postmenopausal women in 
verbal fluency and working memory tasks. Perhaps younger postmenopausal women would have 
shown lower scores than perimenopausal women on these tasks, as in research by Weber et al. 
(2013), where women only in their first year of menopause performed significantly worse than 
late-postmenopausal women on similar cognitive tasks. The initial loss of estrogen during the 
menopause transition is an extreme disruption in women that leads to various symptoms and 
cognitive changes. Therefore, cognitive impairment may begin in the perimenopausal stage, 
when menstrual cycles begin to become irregular. When women lose estrogen and menstrual 
cycles, there may be even greater changes in cognition during this initial time period of 
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postmenopause. Thus, after a few months, women may develop abilities to compensate for this 
drastic hormone change and regulate back to normal cognitive functioning. This demonstrates 
that cognition may not decline linearly across the menopause transition and women may 
experience both declines and improvements.  
Both postmenopausal women with diabetes and without diabetes had higher ratings of 
depression, as noted by Table 2. Additionally, these women reported feelings of mood swings, 
worrying needlessly, and fatigue with high frequency on the Menopause Symptom Checklist, as 
noted in the results section. These data align with previous research by Weber et al. (2014) in 
that perimenopausal and postmenopausal women were at a significantly increased risk for having 
depressive symptoms and being diagnosed with clinical depression as compared to 
premenopausal women. Individuals with diabetes also seemed to have increased risk for 
depression when considering risk factors such as diabetic complications, education level, poor 
glycemic control, and sex (Andreoulakis et al., 2012). Therefore, the postmenopausal women 
with diabetes in this study may have been experiencing the additive risks for depression from 
both menopause and diabetes.  
 As predicted, postmenopausal women with diabetes showed lower scores than both 
perimenopausal and postmenopausal women without diabetes on the Letter Number Sequencing 
Test and the Trail Making Test. This suggests differences in working memory as well as 
attention and task switching. Postmenopausal women with diabetes showed lower scores than 
postmenopausal women without diabetes but showed higher scores than perimenopausal women 
without diabetes on the Verbal Fluency Test, which was not predicted. This suggests differences 
in executive control between postmenopausal women with and without diabetes, but not between 
perimenopausal women and postmenopausal women with diabetes. This may be due to the small 
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sample size or it may be that diabetes’ effects on cognition have a more significant effect on 
women later in the menopause transition. In other words, the effects of diabetes may not be as 
measurable during the perimenopausal stage. There is no previous research on how diabetes may 
affect cognition in the stages of menopause differently. Gregg et al. (2000) did note, however, 
that cognitive impairment worsened as duration of diabetes increased. This study did not 
examine estrogen as it presented both men and women, but cognitive decline was greatest in 
women who had been diagnosed with diabetes for at least 15 years (Gregg et al., 2000). Of the 
two subjects with diabetes in our study, the subject who had been diagnosed with diabetes 13 
years ago showed worse scores on all tests as compared to the other subject who had been 
diagnosed three years ago. Long-term type II diabetes has many negative consequences on the 
brain in that high blood glucose can impact the brain’s functional connectivity (Klein et al., 
2003). The effects this has on cognition may worsen with time, as high glucose levels continue to 
disrupt brain tissue. The changes in neuronal structure that negatively impact cognition could 
also be worsened if these glucose levels were not continuously monitored and controlled. 
Interestingly, the subject who had a longer disease duration reported that she did not properly 
monitor her glucose levels, nor did she know her typical morning and night levels. The other 
subject, however, did report properly monitoring and managing her glucose levels adequately. 
This may also be important to note when examining the differences between their scores on the 
cognitive measures. If an individual does not adequately manage her sugar levels, they may rise 
or fall to numbers that are dangerous for the brain. It would be interesting to examine the 
differences in cognition due to diabetes care, management, and duration of diabetes to examine 
how menopause is related as previous research by Mauvais et al. (2017) suggested that estrogen 
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may delay the onset of type II diabetes. From this information, it is hypothesized that diabetes 
may cause additive cognitive impairment over time, as the disease takes a toll on the brain.  
Limitations 
 The current study has multiple limitations that are important to note. The sample size was 
small, with only eight subjects total. Subject recruitment was difficult due to the age range of 
women being studied. Middle-aged women are likely working. We had minimal response to the 
advertisements hung around town and in Seven Days newspaper. Subject recruitment may have 
also been hindered by the short period of time for data collection.  
Due to the small sample size, these data do not provide a representative sample. There 
were only two subjects with diabetes versus six subjects without diabetes, preventing statistical 
analyses between groups. The women in the current study were all high functioning women that 
all received high school degrees and seven received a bachelor’s degree or higher. All women 
were well educated, Caucasian, and fulltime employees. Therefore, these data may not be 
generalized to all populations.  
Lastly, the current study was a short cross-sectional design in which participation in the 
study required one study visit without any follow-ups. A cross-sectional design still allows for 
comparisons between groups, if a large sample size is present. However, it does not allow for the 
observation of changes in individuals across the menopause transition. 
Future Research 
There is a clear need for further research in this field to not only examine the 
relationships between menopause, diabetes, and cognition in middle-aged women but also to 
examine the mechanisms underlying the interactions between diabetes and menopause.   
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 As mentioned in the limitations, the present study was conducted over a few short months 
with a one-time study visit for each subject. Longitudinal studies that follow women with 
diabetes through their menopause transition, from premenopause to late-postmenopause, would 
allow researchers to examine when and how cognitive decline begins in women with diabetes. It 
may then be possible to approximate the stage of menopause that is associated with the highest 
cognitive decline when linked with diabetes, so that future studies examining ways to mitigate 
cognitive change can target this group at increased risk for cognitive decline.  
 Additionally, there are few studies in the field utilizing imaging techniques to assess 
where in the brain structural changes are seen and how these changes may relate to the cognitive 
decline. Weber et al. (2013) noted that estrogen can influence hippocampal and prefrontal cortex 
functions, which indicates that these structures may be involved in the cognitive impairment 
associated with menopause. Additionally, the study described earlier by Heijer et al. (2003) 
noted more hippocampal and amygdalar atrophy on MRI in subjects with diabetes. Thus, it may 
be possible to see structural change in the hippocampus in menopausal women with diabetes as 
compared to women without diabetes on MRI. Such a study would allow researchers to examine 
where changes in the brain occur and how that relates to cognitive decline. Studies may then 
begin to investigate the mechanistic properties underlying combined influence of menopause and 
diabetes on cognition. Understanding these mechanisms could allow researchers to examine 
therapies that target degeneration in the impacted regions of the brain.  
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Final Conclusions 
While we did not compute statistical comparisons on these data because of the small 
sample size, it is still important to highlight the need for further research in this field. This was 
the first study to attempt to examine the effects of diabetes in middle-aged women to determine 
how these effects differ at various stages of the menopause transition. Though interesting trends 
were found, future large scale, longitudinal studies with imaging and cognitive assessments are 
needed to begin to fully understand the interactions between diabetes, menopause, and cognition.  
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